



VISION DIRECT LABS LLC

89 Auburn Street
Suite 1007
Portland,
ME 04103
USA

ANALYSIS CERTIFICATE - DRAGONFLY CBD PATCH

LOT NO : HMP2020220901/1

MANUFACTURED : Sept 2022

Construction:

Face Sheet: 0.102 mm clear FT-200 polyethylene

Adhesive: Moderate molecular weight, non-crosslinking, Acrylic co-polymer pressure sensitive adhesive.

Release Liner: 90 gm per square meter Semi-bleached densified kraft.

Active Ingredients: Each patch indicated to contain :

CBD Isolate 20mg

Size of Patch: 38 mm square with rounded corners.

Active Ingredients per Patch: 19.9965 mg.

CERTIFICATE OF PATCH COMPOSITION:

The computer controlled systems ensure an even coat weight across the entire film at a wet weight of 100 g/m². The calculation we conducted to ensure correct dosing is as follows:


The active adhesive solution contained 13.848% active ingredient. Using this solution patches will be coated with at 13.848 g/m². The size of a 38 x 38 mm patch is 0.001444 g/m².

Therefore, the manufacturing dosing level of active load on a patch, using the adhesive solution analysed in this report, is **19.9965 mg** (13.848 x 0.001444).

Total coated film area is 329.8m²
Total active adhesive used is 42.98 kgs (329.8.m² x 100gsm + 10kgs waste)

CBD Isolate Total Added 5.952kg = Total Active Coat Weight 144.40mg/patch @ 13.848% = 19.9965mg

We certify that the above mentioned ingredients and amounts listed have been added to the adhesive in the amounts stated and are present in the coated materials. The roll goods were manufactured in Sept 2022 with an expiration date of 3 years from manufacture of Sept 2025

Signature: 
Jonathan L. C. Tell



This information is being supplied on a "CONFIDENTIAL" basis and only intended for use for Registration with the Health Department. Any use of this information for promotional use is prohibited without the written permission from Vision Direct LLC. It is also understood that a copy of any registration granted from any Health Department will be forwarded to Vision Direct LLC.



VISION DIRECT LABS LLC

89 Auburn Street
Suite 1007
Portland,
ME 04103
USA

**CERTIFICATE OF MANUFACTURE
and COUNTRY OF ORIGIN**

This document certifies that the following product is manufactured by Vision Direct LLC and is a product of the United Kingdom.

Product Name: CBD Patch

Product Code: HMP20DF

Batch : HMP2020220901/1

Description: Clear 38mm x 38mm patch.

Ingredients:

CBD Isolate

Intended Use Apply one patch on the body for twenty four hours to receive the maximum in therapeutic benefits.

Document Prepared for: dragonfly

Vision Direct LLC further certifies that the production facility at which product HMP15PZ is manufactured is registered as a manufacturer with the appropriate state and local government authorities, operating according to a set of procedures which are laid down in the form required by ISO 9001.

The company operates under the terms and requirements of COSHH (Care of Substances Hazardous to Health) legislation, and is audited regularly. Transport of hazardous materials is carried out according to CHIP regulations.

Signed: _____

This information is being supplied on a "CONFIDENTIAL" basis and only intended for use for Registration with the Health Department. Any use of this information for promotional use is prohibited without the written permission from Vision Direct LLC. It is also understood that a copy of any registration granted from any Health Department will be forwarded to Vision Direct LLC.





VISION DIRECT LLC

DECLARATION OF CONFORMITY

The undersigned, representing the following supplier and the authorised representative established within the community

**Vision Direct LLC
89 Auburn Street
Suite 1007
Portland
Maine
04103-2103**

**Revolution Health Products Ltd
8 Castlegate, Tickhill
Doncaster
South Yorkshire
United Kingdom**

Herewith declare that the Products **Topically Applied Adhesive Strips**
Product identification (brand) **CBD Patch CBD20DF (Dragonfly)**

Are in conformity with the following EC Directive(s) when used in accordance with the usage instructions contained in the product documentation.

93/42/EEC as amended by 2007/47/EC Medical Devices Directive Class 1

Authorised Representative in the Community:

Jonathan Bowtell
CEO

Date 7/20/2022



89 Auburn Street
Suite 1007
Portland
ME 04103
info@visionmeditechgroup.com